Introduction
Adoptive cell therapy (ACT) with TCR modified T cells is no longer a mere preclinical strategy but is now analyzed in phase I clinical trials. The rationale behind the development of TCR modified T cell therapy is persuasive. For tumor-associated antigens for which the endogenous T cell repertoire is limited in size or activity due to self-tolerance, it seems reasonable to supply this repertoire by infusion of genetically engineered tumor specific T cells 1 . The status of the field can be summarized as follows. First, TCR modified T cells can reliably be generated against a large number of tumorassociated antigens [2] [3] [4] [5] [6] [7] . Second, engineering approaches such as optimization of TCR gene sequences 8, 9 , inclusion of murine constant domains 10 , or inclusion of an engineered disulfide bond 11, 12 can be utilized to enhance the expression of the introduced T cell receptor. These latter two approaches can also suppress the formation of mixed TCR dimers that are composed of endogenous and exogeneous TCR chains, likely contributing to the safety of the therapy 13 . Third, TCR modified T
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A first set of studies that focused on the feasibility of TCR gene transfer in murine models demonstrated that TCR modified CD8 + and CD4 + T cells react to antigen encounter in vivo [14] [15] [16] , even when the endogenous T cell repertoire is non-responsive (chapters 4 17 and 5). More recent work has provided first evidence for the clinical potential of TCR gene therapy 18 . In this phase I clinical trial, patients with metastatic melanoma were treated with autologous T lymphocytes engineered to express a TCR specific for the melanocyte differentiation antigen MART-I. Notably, following T cell infusion, tumor regression was observed in 2 patients and these clinical responses appeared to correlate with the magnitude of the TCR modified T cell response upon infusion.
While these preclinical and clinical data suggest that the underlying rationale behind this therapy is valid, it is important to emphasize that substantial improvements are required to transform TCR gene transfer into a clinically meaningful strategy. Specifically, the clinical data obtained to date have shown that persistence of TCR gene modified T cells in individual patients is variable, and that the expression of the introduced MART-I-specific TCR was markedly lower than TCR expression from the endogenous loci 18 . Perhaps because of this, with a response rate of 2/17, clinical effectiveness of TCR gene transfer was clearly less than that of prior trials by the Rosenberg group that involved infusion of ex vivo expanded tumor-infiltrating lymphocytes 19, 20 . The results from murine studies support the notion that the current protocols for adoptive therapy with TCR modified T cells are still suboptimal. Specifically, while infusion of TCR modified T cells can be used to halt the outgrowth of transplantable 17 and spontaneously developing tumors (chapter 5) in otherwise self-tolerant situations, complete remissions are achieved only rarely 17 .
Based on these preclinical and clinical data we concluded that, while the genetic engineering of T cell specificities can now be achieved, the functional activity of the resultant cells requires a substantial improvement. Within this study, we set out to examine a set of parameters that could influence the anti-tumor activity of TCR modified T cells in vivo. We reasoned that improvements in TCR gene therapy could involve one of either three factors: First, alterations within the format of the introduced TCR genes; Second, modification of the cell graft; Third, adjustment of the host environment that the gene modified T cells encounter upon infusion. Within this study we chose to analyze one parameter representing each of these three different aspects.
Retroviral constructs, T cell transduction and tumor experiments. The pMX-OT-ID-IRES-OT-IE retrovirus encoding the non-modified OT-I TCR genes (pMX-OT-I wt ) has been described 17 . Optimized OT-I TCR genes were produced by GeneArt (GeneArt GmbH, Regensburg, Germany) and cloned into the retroviral vector pMX to create pMX-OT-ID opt -IRES-OT-IE opt (pMX-OT-I opt ). Mouse splenocytes were modified by retroviral transduction as described previously 14 . The B16-OVA cell line expressing the C-terminal part of ovalbumin (OVA) (aa 161-385) and the murine CD4 molecule as a marker gene product 17 was cultured in RPMI supplemented with 10% FCS and 100 U/ml penicillin and 100 Pg/ml streptomycin. Prior to inoculation, cells were washed three times with HBSS (Gibco, Auckland, New Zealand) to remove serum components and 1x10 5 cells were injected subcutaneously in the right flank.
Tumors were measured with calipers and mice were killed once tumors reached an average diameter of 10mm. For ex vivo analysis of antigen expression, sliced tumors were incubated in medium supplemented with collagenase IV (0.2 mg/ml; Worthington, Lakewood, NJ) and DNaseI (25 Pg/ml;
Roche, Mannheim, Germany) for 20-30 minutes at 37 o C. Single cell suspensions were generated with the aid of a cell strainer (BD Biosciences, Erembodegem, Belgium). Erythrocytes were removed by NH 4 Cl treatment, and cells were subsequently cultured in RPMI supplemented with 10% FCS and antibiotics. After 1-3 days of culture, expression levels of the CD4 marker gene product on cells recovered from tumor material were measured as a surrogate marker of OVA expression, and were compared to CD4 expression levels on cultured B16-OVA and B16 cell lines. Irradiation-induced host conditioning and viral vaccination. Irradiation-induced host conditioning was achieved by 5 Gy total body irradiation (TBI) with a radiobiology constant potential X-ray unit (Pantak HF-320; Pantak Limited, Reading, United Kingdom), one day before adoptive cell transfer. For viral vaccination, mice were infected intraperitoneally at the indicated timepoints with 1x10 6 PFU of a recombinant vaccinia strain that expresses ovalbumin (rVV-OVA) 22 .
Measurement of blood glucose levels and treatment of diabetes. To monitor the onset and severity of diabetes, mice were weighed regularly throughout experiments and in case of weight loss, blood
Optimizing TCR gene transfer glucose levels were monitored by Accu-Check Compact (Roche Diagnostics, Germany) measurement. Mice were considered diabetic when blood glucose levels reached > 20 mmol/L. To allow long-term follow-up, diabetic mice were treated by subcutaneous introduction of insulin implants according to the manufacturer's protocol (©LinShin Canada, Inc.).
Statistics. Survival curves were compared using a Log-rank (Mantel-Cox) test. Immune responses were compared using a Student T-test. P values less than 0.05 were considered significant.
Results
ACT with TCR transduced T cells upon irradiation-induced host conditioning. Two fundamentally distinct strategies can be used to drive the expansion of adoptively transferred T cells in vivo. When the cognate antigen of the introduced T cells is provided by vaccination, TCR triggering is induced and the resulting T cell proliferation and T cell differentiation parallels that seen during physiological T cell responses. As an alternative to antigen-specific vaccination, host conditioning regimens such as non-myeloablative chemotherapy or irradiation can be utilized to promote the outgrowth of infused T cell populations. The mechanisms that drive T cell proliferation and differentiation in the latter case are thought to be substantially more diverse. First, the reduction in T cell and NK cell numbers that is achieved by host conditioning leads to an enhanced availability of IL-7 and IL-15, cytokines that can induce T cell proliferation independent of the presence of cognate antigen. In addition, depletion of regulatory T cells and release of adjuvants from intestinal bacteria may further drive T cell activation. Finally, in case tumor-specific T cells are infused into tumorbearing hosts, release of cognate antigen as a consequence of tumor cell death may be an added contributing factor. Importantly, due to the fact that T cell expansion upon vaccination and host conditioning is driven by distinct mechanisms, both the persistence and functional properties of the induced T cell population can differ 23, 24 . Specifically, while vaccination results in the rapid emergence of a highly differentiated pool of effector T cells 25 , T cell populations induced by host conditioning display properties of memory T cells 23 , possibly translating in an enhanced capacity for long-term persistence.
Irradiation-and chemotherapy-induced host conditioning prior to adoptive T cell transfer has been used to enhance the in vivo expansion and anti-tumor effect of TCR-transgenic T cells in mouse models 26 and of tumor-infiltrating lymphocytes (TIL) in melanoma patients 19 . Likewise, in the phase I TCR gene therapy trial by Morgan and colleagues, chemotherapy-induced host conditioning was used with the aim to facilitate engraftment of the infused TCR modified T cells. However, in preceding preclinical studies of TCR gene transfer in mouse models 14, 17 , vaccination rather than host conditioning has been used to drive activation and expansion of the transferred TCR modified T cells, and a comparison of the two strategies has not been made. It is noted that the identification of optimal engraftment regimens for TCR modified T cells is of particular relevance as prior experiments have .1 + cells ~75% of total CD8 + cells at peak, ~40% after 1 month) (Fig. 1C ). These data show that a combination of host conditioning plus transfer of TCR-modified T cells that are rendered reactive against a defined self antigen can lead to a prolonged anti-tumor effect in an otherwise self tolerant setting. Furthermore, this combination yields a T cell repertoire that is markedly skewed towards tumor reactivity.
To modify this mouse model to a setting where a possible enhancing effect of further variations in ACT strategies could be apparent, a second cohort of mice was treated with the same combination of irradiation and T cell infusion, but with treatment starting on day 9. Irradiation of mice in combination with transfer of mock-transduced T cells again had no significant effect on tumor growth nor survival as compared to mice that did not receive any form of treatment. In this setting of delayed T cell therapy, host conditioning in combination with ACT of OT-I transduced T cells still resulted in a clear suppression of tumor growth (Fig 1D-E) . However, tumors continued to progress, resulting in only a moderate increase in survival (20 days versus 34 days; p<0.005), providing a situation where further improvements in ACT strategies should be detectable. Also in this setting, where T cell infusion was performed at day 10 post tumor inoculation, marked T cell responses of TCR modified T cells were apparent in peripheral blood ( Fig 1F) . 
Irradiation-induced host conditioning outperforms vaccination as an engraftment regimen for TCR modified T cells.
Having established that TCR modified T cells proliferate extensively in a conditioned host, we aimed to compare irradiation-induced host conditioning to active vaccination as strategies to boost the anti-tumor potential of infused TCR modified T cells. To this purpose, T cell responses and tumor outgrowth were compared in three groups. In a first experimental group, OT-I TCR transduced T cells were infused at day 10 in tumor bearing RIP-OVA hi mice, and mice were then vaccinated with a recombinant vaccinia virus expressing the OVA antigen (rVV-OVA). In a second group, OT-I TCR transduced T cells were infused at day 10 in tumor bearing RIP-OVA hi mice that had received sublethal TBI one day prior to ACT. Finally, a third group of mice receiving OT-I modified T cells was treated with a combination of sublethal TBI (one day before ACT) plus rVV-OVA vaccination (day 3 post ACT), to assess whether the combined use of the two engraftment regimens would have an additive or synergistic effect. Because in these experiments T cell responses are compared between groups of mice in which endogenous T cell numbers are either unaffected ('rVV-OVA only' group) or highly reduced ('TBI' and 'TBI o rVV-OVA' groups), both the percentages and absolute numbers of TCR modified T cells were determined.
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In vivo activation of OT-I transduced T cells by vaccination with rVV-OVA resulted in a very rapid burst in both the number and frequency of TCR modified T cells, with a peak frequency of TCR modified T cells of 10.3% of CD8 + cells on day 5 after transfer. Comparison of TCR modified T cell numbers in these mice that received rVV-OVA with those in mice that had been pretreated by TBI showed that the absolute number of TCR modified T cells early after transfer was indeed significantly higher in mice that received viral vaccination (p<0.005 at day 7 As expected, the frequencies of TCR modified T cells in mice that received TBI greatly exceeded those in mice treated with rVV-OVA and this difference was particularly apparent at later time points post transfer (e.g. 55% versus 2.3% at day 10 post transfer). Interestingly, when TBI was combined with viral vaccination, this led to only a modest and transient further increase in both absolute numbers ( Fig. 2A right panel) and frequencies ( Fig. 2A left panel) of TCR modified T cells, as compared to the values found in mice conditioned by TBI only. Furthermore, there was a trend towards reduced persistence of TCR modified T cells at later time points upon inclusion of vaccination.
The more prolonged nature of TCR modified T cell responses in mice treated by TBI as compared to vaccination was also reflected in the kinetics of tumor outgrowth. The combination of ACT of OT-I TCR modified T cells plus viral vaccination resulted in a transient delay in tumor growth and a small but significant increase in survival (average 22 versus 27 days; p<0.005) ( Figure 2B -C). The use of TBI as a pre-conditioning regimen led to a somewhat stronger suppression of tumor outgrowth, also resulting in a more pronounced increase in survival (average 22 versus 31 days; p<0.005). Interestingly, in mice that were treated by TBI, subsequent vaccination with rVV-OVA did not significantly improve tumor control or survival (average 33 days for TBI-rVV-OVA versus 31 days for TBI; p=0.5). Furthermore, also when viral vaccination was given at a later time point (day 10 post ACT), the combination of vaccination and TBI had no benefit over TBI alone with regard to both tumor development and survival (data not shown). From these data we conclude that in this mouse model, irradiation-induced host conditioning outperforms viral vaccination as a regimen to promote persistence of TCR modified T cells. Furthermore, the data suggest that inclusion of a (viral) vaccine does not significantly enhance the anti-tumor effect of the combination of ACT and TBI.
Gene optimization results in a moderate increase in TCR expression but marked increase in anti-tumor efficacy. As described previously, modification of T cell receptor formats such as inclusion of a second interchain disulfide bond, incorporation of the murine constant domains and optimization of gene sequences can all lead to enhanced expression of the introduced T cell receptor. (Fig. 3C) . This difference resulted in a highly significant increase in survival (p<0.0005, Fig. 3D ). As a second parameter of in vivo T cell function, 7/7 mice that had received OT-I opt TCR transduced T cells developed diabetes, whereas all mice that had received an equal number of T cells transduced the wild type OT-I TCR stayed normoglycaemic (Fig. 3E) . These data show that even for a high affinity TCR that is expressed well without alterations in transgene design, gene optimization has a very significant enhancing effect on the in vivo activity of TCR transduced T cells. (Fig. 4A, left panel) . The preferential outgrowth of T cells that express the OT-I TCR that is observed in particular upon infusion of cell grafts with low TCR modified T cell frequencies suggests that part of the in vivo proliferation is driven by TCR-specific interactions. This is consistent with the possibility that recognition of the cognate OVA antigen by TCR modified T cells provides an additional stimulus beyond that given by the lymphopenic environment. Alternatively, this preferential outgrowth of TCR modified T cells could reflect recognition of MHC molecules presenting endogenous epitopes, which have previously been shown to contribute to homeostatic proliferation in lymphopenic hosts 27 . Although the mice in the 'low passenger' and 'high passenger group' received an equal number of OT-I opt modified T cells, the absolute number of TCR modified T cells in peripheral blood did peak at a lower level in the 'high passenger group' (Fig. 4A, right panel) . Thus, in the presence of a substantial number of passenger cells, the in vivo expansion of TCR modified T cells was reduced, presumably reflecting competition between the TCR modified T cells and passenger cells for homeostatic cues. Importantly, the reduced numbers of TCR modified T cells obtained in vivo upon infusion of grafts with a high number of passenger cells was associated with a substantially reduced capacity to control tumor growth. (Fig. 4B-C) . As a second parameter for in vivo activity of the TCR modified T cell population, type I diabetes was induced in 25% (2/8) of the mice that received TCR modified T cells amidst a high number of passenger cells, but in 100% (7/7) of the mice that received the same number of TCR modified T cells but in a more homogeneous graft (Fig. 4E) .
Precursor frequency of TCR modified T cells determines anti
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Immuno-editing by TCR modified T cells. In mice treated with a combination of TBI and infusion of OT-I opt transduced T cells tumor progression was eventually observed in the large majority of mice ( Fig. 3 and Fig. 4) . Notably, analysis of individual tumor growth curves at this late phase revealed that after varying periods of one to two months in which tumor progression was essentially absent, tumors in individual mice suddenly progressed with kinetics that were comparable to those observed in untreated mice (Fig. 5A ). This rapid late outgrowth of tumors in treated mice suggested an acute loss of tumor control, possibly consistent with the selection of escape variants. To address whether tumor outgrowth after prolonged control by TCR modified T cells could be explained by antigen loss, we collected tumors in a series of experiments and analyzed the expression of the CD4 marker that is translated from the same mRNA as the OVA antigen. This analysis revealed that antigen expression was substantially reduced in tumors obtained from mice that had received TCR modified T cells as compared to tumors obtained from control mice ( Figure 5B ; p<1x10-6). Furthermore, in tumors that escaped immune control after more prolonged periods, evidence for antigen loss became increasingly apparent, consistent with an ongoing process of immune selection. Thus, even though the B16-OVA cell line used was derived from a single cell clone selected for high CD4 expression, the prolonged selection pressure in mice treated by TBI plus TCR modified T cell infusion resulted in the appearance of escape variants with low antigen expression. These data suggest
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that -with regard to the possibility of tumor escape-the targeting of tumor associated antigens such as WT-1 28 or PRAME 29 that contribute to cellular transformation may be preferred. Alternatively, and in analogy with developments in antibody therapeutics, the simultaneous use of two or three TCRs directed against different TAAs will likely suffice to minimize the chance of tumor escape through antigen loss. Clinical implementation of such 'oligoclonal TCR gene transfer' will be an interesting future challenge from both a logistic and regulatory point of view.
Discussion
Inspired by the success of recombinant monoclonal antibodies such as trastuzumab (Herceptin) and rituximab (Rituxan) 30 , much effort has been put into the preclinical testing and clinical implementation of TCR gene therapy, a strategy that can be considered the 'cellular analogue' of adoptive antibody therapy. With the feasibility of TCR gene transfer well established, but faced with the suboptimal antitumor activity of TCR modified T cells both in preclinical models as within the clinic, we here aimed to determine which factors can positively affect the clinical efficacy of TCR gene therapy. As discussed in the introduction, we consider it likely that substantial improvements can be made in three areas, involving either the host, the cell graft or the TCR itself.
The host environment & engraftment of TCR-modified T cells -
We here demonstrate that host conditioning by TBI leads to superior engraftment and anti-tumor efficacy of TCR modified T cells. Whereas viral vaccination resulted in a more pronounced early boost in the number of TCR modified T cells, irradiation-induced host conditioning led to a substantial improvement in the persistence of TCR modified cells. It is noted that because of the rapid growth kinetics of the transplantable tumor model used here, a rapid development of T cell responses is likely to be of greater importance in this model than it will be in the clinical setting, where tumor progression is markedly slower. Thus, the improved tumor control in mice conditioned by TBI as compared to mice receiving viral vaccination seen here may still underestimate the clinical value of chemotherapy-or irradiation-induced host conditioning in TCR gene transfer-based protocols. It seems likely that further improvements can be made in conditioning regimens for ACT. For instance, murine data suggest that myeloablative conditioning plus stem cell support results in an enhanced expansion and function of adoptively transferred TCR transgenic T cells 31 . Alternatively, the selective depletion of the cellular subsets that compete for homeostatic cytokines may yield a more targeted approach to facilitate cell engraftment. Finally, blockade of inhibitory pathways by combination with monoclonal antibody therapy against CTLA-4 or PD-1/ PD-L1 may be considered.
TCR transgene design -Alterations in TCR transgene design fall into two classes, those that aim to change the specificity or affinity of the TCR for its cognate antigen and those that aim to increase the expression of the desired TCR DE heterodimer upon T cell modification. Efforts to achieve the latter have stemmed from the observation that non-modified TCR heterodimers are generally expressed at
Optimizing TCR gene transfer low levels upon introduction in human peripheral blood T cells. Recent elegant work by Heemskerk and others has shown that this low expression is due to competition of exogenous TCR chains with endogenous TCR chains for assembly with CD3 components, and due to the formation of mixed dimers of endogenous and exogenous TCR chains. Interestingly, the ability of the exogenous and endogenous TCR to compete for surface expression can vary widely between different TCRs, most likely reflecting the efficiency with which the different TCR heterodimers fold 32 . The OT-I TCR used here can be considered a 'dominant' TCR in that retroviral transduction of mouse T cells with the unmodified TCR leads to TCR transgene expression in a high proportion of cells. Nevertheless, TCR gene optimization still resulted in a modest increase in transduction efficiency and a quite marked effect on the in vivo activity of T cells modified with this TCR. Based on these data it seems plausible that other strategies that have yielded similar increases in TCR expression in vitro (10-12) will also be of significant value to enhance the in vivo function of TCR modified T cells, and a combination of the different strategies may in fact be preferred.
Composition of the cell graft -In a final set of experiments we demonstrated that the frequency of TCR modified T cells within the cell graft determines the efficacy of ACT, even when infused numbers of TCR modified T cells are kept constant. We have considered two non-mutually exclusive explanations for this observation. First, the co-infusion of a large number of unmodified cells may lead to a reduced proliferation and differentiation of the TCR modified T cells by decreasing the availability of cues for homeostatic expansion. Specifically, an increased availability of the IL-7 and IL-15 cytokines has been shown to play an essential role in the enhancement of T cell mediated tumor immunotherapy after lymphodepleting host conditioning and the co-transfer of irrelevant T cells and NK cells may simply limit this effect 33, 34 . Alternatively, regulatory T cells (T-regs) have been shown to suppress immune responses towards B16 melanoma 35, 36 , and the infusion of large numbers of passenger cells may result in a more rapid restoration in regulatory T cell number following host conditioning. In both cases, the development of approaches that would result in a more selective or fully selective infusion of TCR-modified T cells would be desirable. A substantial enrichment of gene modified T cells prior to ACT may be achieved by selection of T cells expressing the VE (or VD) element that is used by the introduced TCR, although this would not select against TCR modified T cells that predominantly express this TCR chain in the form of mixed dimers. A more stringent selection may possibly be achieved by MHC tetramer 37 or reversible MHC tetramer-based isolation 38 of TCR modified T cells, and in this light the development of a conditional ligand-based platform for the creation of GMP-grade MHC multimers seems worth pursuing 39 . Finally, while we have here focussed on the frequency of TCR modified T cells within the graft, it seems plausible that alterations in the type of T cells that is used for viral modification may also be beneficial. For instance, the selective modification of T cells with a high capacity for immune reconstitution may potentially be attractive 40 . As a somewhat more futuristic approach, more defined populations of TCR modified T cells for adoptive therapy may conceivably also be generated in systems in which TCR modified T
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cells can be obtained in vitro from hematopoietic progenitor cells 41, 42 , with the added benefit that endogenous TCR rearrangement is at least partially suppressed 41 .
Here we have shown that the effectiveness of TCR gene transfer-based immunotherapy can be substantially enhanced in three ways that each affect a different part of the procedure: 1). Irradiationinduced host conditioning results in the long term persistence of TCR transduced T cells and appears preferable over active vaccination. 2). The use of vectors encoding TCR sequences optimized for expression yields redirected T cells with a substantially increased capacity for in vivo tumor control, and this effect may well extend to other alterations in TCR design that result in increased expression.
3). The infusion of grafts in which TCR-modified T cells are present at a high frequency is preferable over infusion of an equal number of TCR modified T cells amidst a higher number of irrelevant cells, and is correlated with an enhanced in vivo expansion of the desired tumor-specific T cell population.
The combined clinical implementation of these approaches appears warranted.
